Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
4 recherche sur le mot-clé 'Caregiver stress'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
How Are Child Restricted and Repetitive Behaviors Associated with Caregiver Stress Over Time? A Parallel Process Multilevel Growth Model / Clare HARROP in Journal of Autism and Developmental Disorders, 46-5 (May 2016)
[article]
Titre : How Are Child Restricted and Repetitive Behaviors Associated with Caregiver Stress Over Time? A Parallel Process Multilevel Growth Model Type de document : Texte imprimé et/ou numérique Auteurs : Clare HARROP, Auteur ; Matthew MCBEE, Auteur ; Brian A. BOYD, Auteur Article en page(s) : p.1773-1783 Langues : Anglais (eng) Mots-clés : Autism Caregiver stress Restricted and repetitive behaviors Index. décimale : PER Périodiques Résumé : The impact of raising a child with autism spectrum disorder (ASD) is frequently accompanied by elevated caregiver stress. Examining the variables that predict these elevated rates will help us understand how caregiver stress is impacted by and impacts child behaviors. This study explored how restricted and repetitive behaviors (RRBs) contributed concurrently and longitudinally to caregiver stress in a large sample of preschoolers with ASD using parallel process multilevel growth models. Results indicated that initial rates of and change in RRBs predicted fluctuations in caregiver stress over time. When caregivers reported increased child RRBs, this was mirrored by increases in caregiver stress. Our data support the importance of targeted treatments for RRBs as change in this domain may lead to improvements in caregiver wellbeing. En ligne : http://dx.doi.org/10.1007/s10803-016-2707-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=288
in Journal of Autism and Developmental Disorders > 46-5 (May 2016) . - p.1773-1783[article] How Are Child Restricted and Repetitive Behaviors Associated with Caregiver Stress Over Time? A Parallel Process Multilevel Growth Model [Texte imprimé et/ou numérique] / Clare HARROP, Auteur ; Matthew MCBEE, Auteur ; Brian A. BOYD, Auteur . - p.1773-1783.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 46-5 (May 2016) . - p.1773-1783
Mots-clés : Autism Caregiver stress Restricted and repetitive behaviors Index. décimale : PER Périodiques Résumé : The impact of raising a child with autism spectrum disorder (ASD) is frequently accompanied by elevated caregiver stress. Examining the variables that predict these elevated rates will help us understand how caregiver stress is impacted by and impacts child behaviors. This study explored how restricted and repetitive behaviors (RRBs) contributed concurrently and longitudinally to caregiver stress in a large sample of preschoolers with ASD using parallel process multilevel growth models. Results indicated that initial rates of and change in RRBs predicted fluctuations in caregiver stress over time. When caregivers reported increased child RRBs, this was mirrored by increases in caregiver stress. Our data support the importance of targeted treatments for RRBs as change in this domain may lead to improvements in caregiver wellbeing. En ligne : http://dx.doi.org/10.1007/s10803-016-2707-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=288 Effects of written disclosure on psychophysiological stress among parents of children with autism: A randomized controlled pilot study / Nikko S. DA PAZ in Research in Autism Spectrum Disorders, 53 (September 2018)
[article]
Titre : Effects of written disclosure on psychophysiological stress among parents of children with autism: A randomized controlled pilot study Type de document : Texte imprimé et/ou numérique Auteurs : Nikko S. DA PAZ, Auteur ; Jan L. WALLANDER, Auteur ; Jitske TIEMENSMA, Auteur Article en page(s) : p.7-17 Langues : Anglais (eng) Mots-clés : Autism spectrum disorders Parent intervention Caregiver stress Written disclosure Index. décimale : PER Périodiques Résumé : Background In comparison to parents of typically functioning children or parents of children with other developmental disabilities (i.e. Down’s syndrome or cerebral palsy), parents or caregivers of children with an autism spectrum disorder (ASD) sustain a greater incidence of depression, anxiety, and emotional distress. It is imperative to identify effective methods that target improvement to caregiver mental health. Method A randomized controlled pilot study was conducted to investigate the effect of a written disclosure intervention (expressive writing about traumatic events versus neutral events) on the psychophysiological stress of 71 parents (age 23–62) caring for a child with ASD. Self-reported measures of stress (parenting stress, caregiver burden, and global stress) and a stress biomarker (cortisol awakening response) were evaluated at baseline and 6-month follow-up. Adjusting for baseline values, we performed a univariate analysis of covariance to test directional hypotheses that parents in the treatment group would show a reduction in subjective stress and improvement in physiological stress over time. Results As expected, treatment group parents displayed healthier cortisol activity and reported less global stress compared to controls. Whereas within group analyses indicated all parents experienced improvement in parenting stress and caregiver burden over time, there was no significant treatment effect for these caregiving-specific stress measures. Conclusions Within this pilot study, written disclosure appeared beneficial to caregiver psychophysiological stress. However, due to the provision of substantial participant adherence support, we refrain from suggesting feasibility. Nonetheless, improvement of mental health pathology in parents of children with ASD is both significant and timely. En ligne : https://doi.org/10.1016/j.rasd.2018.05.007 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=368
in Research in Autism Spectrum Disorders > 53 (September 2018) . - p.7-17[article] Effects of written disclosure on psychophysiological stress among parents of children with autism: A randomized controlled pilot study [Texte imprimé et/ou numérique] / Nikko S. DA PAZ, Auteur ; Jan L. WALLANDER, Auteur ; Jitske TIEMENSMA, Auteur . - p.7-17.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 53 (September 2018) . - p.7-17
Mots-clés : Autism spectrum disorders Parent intervention Caregiver stress Written disclosure Index. décimale : PER Périodiques Résumé : Background In comparison to parents of typically functioning children or parents of children with other developmental disabilities (i.e. Down’s syndrome or cerebral palsy), parents or caregivers of children with an autism spectrum disorder (ASD) sustain a greater incidence of depression, anxiety, and emotional distress. It is imperative to identify effective methods that target improvement to caregiver mental health. Method A randomized controlled pilot study was conducted to investigate the effect of a written disclosure intervention (expressive writing about traumatic events versus neutral events) on the psychophysiological stress of 71 parents (age 23–62) caring for a child with ASD. Self-reported measures of stress (parenting stress, caregiver burden, and global stress) and a stress biomarker (cortisol awakening response) were evaluated at baseline and 6-month follow-up. Adjusting for baseline values, we performed a univariate analysis of covariance to test directional hypotheses that parents in the treatment group would show a reduction in subjective stress and improvement in physiological stress over time. Results As expected, treatment group parents displayed healthier cortisol activity and reported less global stress compared to controls. Whereas within group analyses indicated all parents experienced improvement in parenting stress and caregiver burden over time, there was no significant treatment effect for these caregiving-specific stress measures. Conclusions Within this pilot study, written disclosure appeared beneficial to caregiver psychophysiological stress. However, due to the provision of substantial participant adherence support, we refrain from suggesting feasibility. Nonetheless, improvement of mental health pathology in parents of children with ASD is both significant and timely. En ligne : https://doi.org/10.1016/j.rasd.2018.05.007 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=368 Examining the Efficacy of a Family Peer Advocate Model for Black and Hispanic Caregivers of Children with Autism Spectrum Disorder / J. M. JAMISON in Journal of Autism and Developmental Disorders, 47-5 (May 2017)
[article]
Titre : Examining the Efficacy of a Family Peer Advocate Model for Black and Hispanic Caregivers of Children with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : J. M. JAMISON, Auteur ; E. FOURIE, Auteur ; P. M. SIPER, Auteur ; M. P. TRELLES, Auteur ; Julia GEORGE-JONES, Auteur ; A. BUXBAUM GRICE, Auteur ; J. KRATA, Auteur ; E. HOLL, Auteur ; J. SHAOUL, Auteur ; B. HERNANDEZ, Auteur ; L. MITCHELL, Auteur ; M. M. MCKAY, Auteur ; Joseph D. BUXBAUM, Auteur ; Alexander KOLEVZON, Auteur Article en page(s) : p.1314-1322 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder Family peer advocate Minority Caregiver stress Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) affects individuals across all racial and ethnic groups, yet rates of diagnosis are disproportionately higher for Black and Hispanic children. Caregivers of children with ASD experience significant stressors, which have been associated with parental strain, inadequate utilization of mental health services and lower quality of life. The family peer advocate (FPA) model has been utilized across service delivery systems to provide family-to-family support, facilitate engagement, and increase access to care. This study used a randomized controlled design to examine the efficacy of FPAs in a racially and ethnically diverse sample. Results demonstrate significantly increased knowledge of ASD and reduced levels of stress for caregivers who received the FPA intervention as compared to treatment as usual. En ligne : http://dx.doi.org/10.1007/s10803-017-3045-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=305
in Journal of Autism and Developmental Disorders > 47-5 (May 2017) . - p.1314-1322[article] Examining the Efficacy of a Family Peer Advocate Model for Black and Hispanic Caregivers of Children with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / J. M. JAMISON, Auteur ; E. FOURIE, Auteur ; P. M. SIPER, Auteur ; M. P. TRELLES, Auteur ; Julia GEORGE-JONES, Auteur ; A. BUXBAUM GRICE, Auteur ; J. KRATA, Auteur ; E. HOLL, Auteur ; J. SHAOUL, Auteur ; B. HERNANDEZ, Auteur ; L. MITCHELL, Auteur ; M. M. MCKAY, Auteur ; Joseph D. BUXBAUM, Auteur ; Alexander KOLEVZON, Auteur . - p.1314-1322.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 47-5 (May 2017) . - p.1314-1322
Mots-clés : Autism spectrum disorder Family peer advocate Minority Caregiver stress Index. décimale : PER Périodiques Résumé : Autism spectrum disorder (ASD) affects individuals across all racial and ethnic groups, yet rates of diagnosis are disproportionately higher for Black and Hispanic children. Caregivers of children with ASD experience significant stressors, which have been associated with parental strain, inadequate utilization of mental health services and lower quality of life. The family peer advocate (FPA) model has been utilized across service delivery systems to provide family-to-family support, facilitate engagement, and increase access to care. This study used a randomized controlled design to examine the efficacy of FPAs in a racially and ethnically diverse sample. Results demonstrate significantly increased knowledge of ASD and reduced levels of stress for caregivers who received the FPA intervention as compared to treatment as usual. En ligne : http://dx.doi.org/10.1007/s10803-017-3045-0 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=305 Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis / Spyridon SIAFIS in Molecular Autism, 13 (2022)
[article]
Titre : Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis Type de document : Texte imprimé et/ou numérique Auteurs : Spyridon SIAFIS, Auteur ; O?ulcan ÇIRAY, Auteur ; Hui WU, Auteur ; Johannes SCHNEIDER-THOMA, Auteur ; Irene BIGHELLI, Auteur ; Marc KRAUSE, Auteur ; Alessandro RODOLICO, Auteur ; Anna CERASO, Auteur ; Giacomo DESTE, Auteur ; Maximilian HUHN, Auteur ; David FRAGUAS, Auteur ; Antonia SAN JOSE CACERES, Auteur ; Dimitris MAVRIDIS, Auteur ; Tony CHARMAN, Auteur ; Declan G. MURPHY, Auteur ; Mara PARELLADA, Auteur ; Celso ARANGO, Auteur ; Stefan LEUCHT, Auteur Article en page(s) : 10 p. Langues : Anglais (eng) Mots-clés : Adolescent Adult Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder/drug therapy Child Humans Network Meta-Analysis Oxytocin/therapeutic use Risperidone/therapeutic use Adhd Anxiety Autism Caregiver stress Irritability Meta-analysis Response Restricted and repetitive behaviors Social communication Treatment Index. décimale : PER Périodiques Résumé : BACKGROUND: There is still no approved medication for the core symptoms of autism spectrum disorder (ASD). This network meta-analysis investigated pharmacological and dietary-supplement treatments for ASD. METHODS: We searched for randomized-controlled-trials (RCTs) with a minimum duration of seven days in ClinicalTrials.gov, EMBASE, MEDLINE, PsycINFO, WHO-ICTRP (from inception up to July 8, 2018), CENTRAL and PubMed (up to November 3, 2021). The co-primary outcomes were core symptoms (social-communication difficulties-SCD, repetitive behaviors-RB, overall core symptoms-OCS) measured by validated scales and standardized-mean-differences (SMDs). Associated symptoms, e.g., irritability/aggression and attention-deficit/hyperactivity disorder (ADHD) symptoms, dropouts and important side-effects, were investigated as secondary outcomes. Studies in children/adolescents and adults were analyzed separately in random-effects pairwise and network meta-analyses. RESULTS: We analyzed data for 41 drugs and 17 dietary-supplements, from 125 RCTs (n=7450 participants) in children/adolescents and 18 RCTs (n=1104) in adults. The following medications could improve at least one core symptom domain in comparison with placebo: aripiprazole (k=6 studies in analysis, SCD: SMD=0.27 95% CI [0.09, 0.44], RB: 0.48 [0.26, 0.70]), atomoxetine (k=3, RB:0.49 [0.18, 0.80]), bumetanide (k=4, RB: 0.35 [0.09, 0.62], OCS: 0.61 [0.31, 0.91]), and risperidone (k=4, SCM: 0.31 [0.06, 0.55], RB: 0.60 [0.29, 0.90]; k=3, OCS: 1.18 [0.75, 1.61]) in children/adolescents; fluoxetine (k=1, RB: 1.20 [0.45, 1.96]), fluvoxamine (k=1, RB: 1.04 [0.27, 1.81]), oxytocin (k=6, RB:0.41 [0.16, 0.66]) and risperidone (k=1, RB: 0.97 [0.21,1.74]) in adults. There were some indications of improvement by carnosine, haloperidol, folinic acid, guanfacine, omega-3-fatty-acids, probiotics, sulforaphane, tideglusib and valproate, yet imprecise and not robust. Confidence in these estimates was very low or low, except moderate for oxytocin. Medications differed substantially in improving associated symptoms, and in their side-effect profiles. LIMITATIONS: Most of the studies were inadequately powered (sample sizes of 20-80 participants), with short duration (8-13 weeks), and about a third focused on associated symptoms. Networks were mainly star-shaped, and there were indications of reporting bias. There was no optimal rating scale measuring change in core symptoms. CONCLUSIONS: Some medications could improve core symptoms, although this could be likely secondary to the improvement of associated symptoms. Evidence on their efficacy and safety is preliminary; therefore, routine prescription of medications for the core symptoms cannot be recommended. Trial registration PROSPERO-ID CRD42019125317. En ligne : http://dx.doi.org/10.1186/s13229-022-00488-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477
in Molecular Autism > 13 (2022) . - 10 p.[article] Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis [Texte imprimé et/ou numérique] / Spyridon SIAFIS, Auteur ; O?ulcan ÇIRAY, Auteur ; Hui WU, Auteur ; Johannes SCHNEIDER-THOMA, Auteur ; Irene BIGHELLI, Auteur ; Marc KRAUSE, Auteur ; Alessandro RODOLICO, Auteur ; Anna CERASO, Auteur ; Giacomo DESTE, Auteur ; Maximilian HUHN, Auteur ; David FRAGUAS, Auteur ; Antonia SAN JOSE CACERES, Auteur ; Dimitris MAVRIDIS, Auteur ; Tony CHARMAN, Auteur ; Declan G. MURPHY, Auteur ; Mara PARELLADA, Auteur ; Celso ARANGO, Auteur ; Stefan LEUCHT, Auteur . - 10 p.
Langues : Anglais (eng)
in Molecular Autism > 13 (2022) . - 10 p.
Mots-clés : Adolescent Adult Attention Deficit Disorder with Hyperactivity Autism Spectrum Disorder/drug therapy Child Humans Network Meta-Analysis Oxytocin/therapeutic use Risperidone/therapeutic use Adhd Anxiety Autism Caregiver stress Irritability Meta-analysis Response Restricted and repetitive behaviors Social communication Treatment Index. décimale : PER Périodiques Résumé : BACKGROUND: There is still no approved medication for the core symptoms of autism spectrum disorder (ASD). This network meta-analysis investigated pharmacological and dietary-supplement treatments for ASD. METHODS: We searched for randomized-controlled-trials (RCTs) with a minimum duration of seven days in ClinicalTrials.gov, EMBASE, MEDLINE, PsycINFO, WHO-ICTRP (from inception up to July 8, 2018), CENTRAL and PubMed (up to November 3, 2021). The co-primary outcomes were core symptoms (social-communication difficulties-SCD, repetitive behaviors-RB, overall core symptoms-OCS) measured by validated scales and standardized-mean-differences (SMDs). Associated symptoms, e.g., irritability/aggression and attention-deficit/hyperactivity disorder (ADHD) symptoms, dropouts and important side-effects, were investigated as secondary outcomes. Studies in children/adolescents and adults were analyzed separately in random-effects pairwise and network meta-analyses. RESULTS: We analyzed data for 41 drugs and 17 dietary-supplements, from 125 RCTs (n=7450 participants) in children/adolescents and 18 RCTs (n=1104) in adults. The following medications could improve at least one core symptom domain in comparison with placebo: aripiprazole (k=6 studies in analysis, SCD: SMD=0.27 95% CI [0.09, 0.44], RB: 0.48 [0.26, 0.70]), atomoxetine (k=3, RB:0.49 [0.18, 0.80]), bumetanide (k=4, RB: 0.35 [0.09, 0.62], OCS: 0.61 [0.31, 0.91]), and risperidone (k=4, SCM: 0.31 [0.06, 0.55], RB: 0.60 [0.29, 0.90]; k=3, OCS: 1.18 [0.75, 1.61]) in children/adolescents; fluoxetine (k=1, RB: 1.20 [0.45, 1.96]), fluvoxamine (k=1, RB: 1.04 [0.27, 1.81]), oxytocin (k=6, RB:0.41 [0.16, 0.66]) and risperidone (k=1, RB: 0.97 [0.21,1.74]) in adults. There were some indications of improvement by carnosine, haloperidol, folinic acid, guanfacine, omega-3-fatty-acids, probiotics, sulforaphane, tideglusib and valproate, yet imprecise and not robust. Confidence in these estimates was very low or low, except moderate for oxytocin. Medications differed substantially in improving associated symptoms, and in their side-effect profiles. LIMITATIONS: Most of the studies were inadequately powered (sample sizes of 20-80 participants), with short duration (8-13 weeks), and about a third focused on associated symptoms. Networks were mainly star-shaped, and there were indications of reporting bias. There was no optimal rating scale measuring change in core symptoms. CONCLUSIONS: Some medications could improve core symptoms, although this could be likely secondary to the improvement of associated symptoms. Evidence on their efficacy and safety is preliminary; therefore, routine prescription of medications for the core symptoms cannot be recommended. Trial registration PROSPERO-ID CRD42019125317. En ligne : http://dx.doi.org/10.1186/s13229-022-00488-4 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477